Einat Gorelik1,2, Reem Masarwa1, Amichai Perlman1, Victoria Rotshild1, Momen Abbasi3, Mordechai Muszkat3, Ilan Matok4. 1. Division of Clinical Pharmacy, School of Pharmacy, The Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, 9112001, Jerusalem, Israel. 2. Department of Pharmacovigilance, Ministry of Health, Jerusalem, Israel. 3. The Department of Medicine, Hadassah University Hospital, Mt. Scopus, Jerusalem, Israel. 4. Division of Clinical Pharmacy, School of Pharmacy, The Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, 9112001, Jerusalem, Israel. ilan.matok@ekmd.huji.ac.il.
Abstract
INTRODUCTION: Several fluoroquinolone antibiotics have been associated with cardiac adverse effects, leading to the withdrawal of some of these agents from the market. Cardiac side effects such as QT prolongation and torsades de pointes (TdP) have also been observed with fluoroquinolones currently on the market. In order to evaluate the cardiac risk of fluoroquinolones as a class, and the comparative risk for each individual drug, we conducted a systematic review, meta-analysis, and network meta-analysis. METHODS: MEDLINE, EMBASE and the Cochrane Library were searched, up to March 2018, for randomized controlled trials, cohort studies, and case-control studies that investigated the association between fluoroquinolone treatment and the risk of cardiovascular events and cardiovascular mortality. We followed the PRISMA 2009 guidelines for data selection and extraction. Outcomes were pooled using random effects models. Direct and indirect comparisons in network meta-analysis were performed using frequentist methods. RESULTS: Thirteen studies were included in our analyses. Fluoroquinolone use was associated with a statistically significant 85% increase in the risk for arrhythmia (odds ratio [OR] 1.85; 95% confidence interval [CI] 1.22-2.81) and 71% increase in the risk for cardiovascular mortality (OR 1.71; 95% CI 1.39-2.09). Moxifloxacin ranked most likely to have the highest risk for arrhythmia (P-score 0.99) and for cardiovascular mortality (P-score 0.95) by network meta-analysis. CONCLUSIONS: Our findings show a significant association between fluoroquinolone use and an increased risk for arrhythmia and cardiovascular mortality. Moxifloxacin ranked with the highest probability for cardiovascular adverse events. Further study is required to determine how to reduce the risk for fluoroquinolone-associated cardiac toxicity.
INTRODUCTION: Several fluoroquinolone antibiotics have been associated with cardiac adverse effects, leading to the withdrawal of some of these agents from the market. Cardiac side effects such as QT prolongation and torsades de pointes (TdP) have also been observed with fluoroquinolones currently on the market. In order to evaluate the cardiac risk of fluoroquinolones as a class, and the comparative risk for each individual drug, we conducted a systematic review, meta-analysis, and network meta-analysis. METHODS: MEDLINE, EMBASE and the Cochrane Library were searched, up to March 2018, for randomized controlled trials, cohort studies, and case-control studies that investigated the association between fluoroquinolone treatment and the risk of cardiovascular events and cardiovascular mortality. We followed the PRISMA 2009 guidelines for data selection and extraction. Outcomes were pooled using random effects models. Direct and indirect comparisons in network meta-analysis were performed using frequentist methods. RESULTS: Thirteen studies were included in our analyses. Fluoroquinolone use was associated with a statistically significant 85% increase in the risk for arrhythmia (odds ratio [OR] 1.85; 95% confidence interval [CI] 1.22-2.81) and 71% increase in the risk for cardiovascular mortality (OR 1.71; 95% CI 1.39-2.09). Moxifloxacin ranked most likely to have the highest risk for arrhythmia (P-score 0.99) and for cardiovascular mortality (P-score 0.95) by network meta-analysis. CONCLUSIONS: Our findings show a significant association between fluoroquinolone use and an increased risk for arrhythmia and cardiovascular mortality. Moxifloxacin ranked with the highest probability for cardiovascular adverse events. Further study is required to determine how to reduce the risk for fluoroquinolone-associated cardiac toxicity.
Authors: Gowtham A Rao; Joshua R Mann; Azza Shoaibi; Charles Lee Bennett; Georges Nahhas; S Scott Sutton; Sony Jacob; Scott M Strayer Journal: Ann Fam Med Date: 2014 Mar-Apr Impact factor: 5.166
Authors: E Raschi; E Poluzzi; F Salvo; A Pariente; F De Ponti; G Marchesini; U Moretti Journal: Nutr Metab Cardiovasc Dis Date: 2018-03-01 Impact factor: 4.222
Authors: Yoriko Heianza; Wenjie Ma; Xiang Li; Yin Cao; Andrew T Chan; Eric B Rimm; Frank B Hu; Kathryn M Rexrode; JoAnn E Manson; Lu Qi Journal: Circ Res Date: 2019-12-17 Impact factor: 17.367
Authors: Magdalene M Assimon; Patrick H Pun; Lily Chin-Hua Wang; Sana M Al-Khatib; M Alan Brookhart; David J Weber; Wolfgang C Winkelmayer; Jennifer E Flythe Journal: JAMA Cardiol Date: 2022-01-01 Impact factor: 30.154
Authors: Lori M Newman; Martin Kankam; Aya Nakamura; Tom Conrad; John Mueller; John O'Donnell; Blaire L Osborn; Kenan Gu; George A Saviolakis Journal: Antimicrob Agents Chemother Date: 2021-10-04 Impact factor: 5.191